Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Rating of “Moderate Buy” from Analysts

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has earned an average recommendation of “Moderate Buy” from the five analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $34.3333.

A number of research firms have commented on UNCY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Monday, December 29th. Guggenheim reiterated a “buy” rating on shares of Unicycive Therapeutics in a research report on Tuesday, December 30th. Finally, Westpark Capital started coverage on Unicycive Therapeutics in a report on Thursday, February 19th. They issued a “buy” rating for the company.

Institutional Trading of Unicycive Therapeutics

Several institutional investors have recently added to or reduced their stakes in UNCY. Vivo Capital LLC raised its holdings in shares of Unicycive Therapeutics by 57.4% during the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock worth $7,804,000 after purchasing an additional 652,901 shares during the period. Millennium Management LLC acquired a new position in shares of Unicycive Therapeutics in the 4th quarter valued at about $5,856,000. Vanguard Group Inc. grew its position in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after buying an additional 52,925 shares during the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Unicycive Therapeutics during the 4th quarter valued at about $1,154,000. Finally, Geode Capital Management LLC raised its stake in Unicycive Therapeutics by 36.2% during the fourth quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock worth $989,000 after acquiring an additional 45,563 shares during the period. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Stock Performance

Shares of UNCY stock opened at $6.83 on Monday. The stock has a market capitalization of $146.78 million, a price-to-earnings ratio of -1.73 and a beta of 1.82. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $11.00. The company’s 50-day simple moving average is $6.53 and its 200-day simple moving average is $5.57.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.